PELLETS*
| Pellets | CAS
No. | Therapeutic
Category | | Omeprazole
Pellets 7.5% | 73590-58-6 | Anti
ulcerative | | Omeprazole
Pellets 8.5% | 73590-58-6 | Anti
ulcerative | | Omeprazole
Pellets 10% | 73590-58-6 | Anti
ulcerative | | Lansoprazole
Pellets 7.5% | 103577-45-3 | Anti
ulcerative | | Lansoprazole
Pellets 8.5% | 103577-45-3 | Anti
ulcerative | | Lansoprazole
Pellets 10% | 103577-45-3 | Anti
histamine | | Lansoprazole
Pellets 11.2% | 103577-45-3 | Anti
ulistamine | | Lansoprazole
Pellets 12.5% | 103577-45-3 | Anti
uistamine | | Pantoprazole
Sodium Pellets 15% | 138786-67-1 | Anti
ulcerative | | Esomeprazole
Magnesium Pellets 8.5% | 217087-09-7 | Anti
ulcerative | | Esomeprazole
Magnesium Pellets 22.5% | 217087-09-7 | Anti
ulcerative | Note: DMF
Available on request.
*The technical and physical manufacturing capabilities
exists with us for these API and their intermediates, however these products will
not be offered to the markets where any product or process patents are not infringing.
During the validity of a patent the research quantities for developing products
for regulatory submissions will be offered only to countries where such exemption
exists (Hatch Waxman / Bolar exemption). While
OREX offers to take work with the clients on patent status verification,
the final responsibility vests with the buyer. Recipients are requested to make
their evaluation and determination as to the patent status prior to use the information
or material in their respective jurisdiction | 
